



SANOPI PASTEUR 

SAUS.SFLU.19.05.2985

Sanofi Pasteur Influenza Vaccines
Chris Whitman

Our Credo

**Sanofi Pasteur believes
in a world in which
no one
suffers or dies from a
vaccine-preventable disease.**

SANOPI PASTEUR  SAUS.SFLU.19.05.2985

5/19 | 2

We Are Focused on Helping to Prevent as Much Influenza Disease As Possible

Vaccinate As Many People as Possible

Deliver the Highest Quality Vaccine(s) Possible

- Change the influenza conversation from infection to influenza disease and its outcomes
- Increase public awareness of the real impact of flu and the value of flu vaccines
- Grow availability and use of vaccines proven to prevent more disease in higher-risk populations
- Invest in better understanding the impact of current vaccines and development of improved solutions

Communications Around Influenza Require the Urgency and Assertiveness Given to Heart Disease and Diabetes

JAHA

Journal of the American Heart Association

Inpatient and Outpatient Infection as a Trigger of Cardiovascular Disease: The ARIC Study

Logan T. Cowan , Pamela L. Lutsey, James S. Pankow, Kunihiro Matsushita, Junichi Ishigami, and Kamakshi Lakshminarayan

 EUROPEAN RESPIRATORY *journal*
FLAGSHIP SCIENTIFIC JOURNAL OF ERS

Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland

Charlotte Warren-Gash, Ruth Blackburn, Heather Whitaker, Jim McMenamin, Andrew C. Hayward
European Respiratory Journal 2018 51: 1701794; DOI: 10.1183/13993003.01794-2017

 The NEW ENGLAND
JOURNAL of MEDICINE

ORIGINAL ARTICLE

Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection

Jeffrey C. Kwong, M.D., Kevin L. Schwartz, M.D., Michael A. Campitelli, M.P.H., Hannah Chung, M.P.H., Natasha S. Crowcroft, M.D., Timothy Kamauchow, Ph.D., Kevin Katz, M.D., Dennis T. Ko, M.D., Allison J. McGeer, M.D., Dayre McNally, M.D., Ph.D., David C. Richardson, M.D., Laura C. Rosella, Ph.D., M.H.Sc., *et al.*

Sanofi Pasteur's Legacy Of Innovating and Investing Continues

- **2018–19 Season: Delivered nearly 70 million doses to the US**

- 22M Fluzone® High-Dose (Influenza Vaccine), representing nearly 2/3 of immunizations in the targeted population
- 12X increase in Flublok® Quadrivalent (Influenza Vaccine) distribution
- Fluzone® Quadrivalent (Influenza Vaccine) remains the most used influenza vaccine brand

- **2019–20 Season: Producing 70 million doses to help protect Americans of all ages**

- 10th year of growth for Fluzone High-Dose demand
- Flublok Quadrivalent growth continues



SANOFI PASTEUR  SAUS.SFLU.19.05.2985